2013-01-15 15:02:35 UTC

Secondary Infections Increase Mortality in Hospitalized Patients With Cirrhosis

Jan. 17, 2013

The results of a prospective, cohort study of patients with cirrhosis with infections at eight North American tertiary-care hepatology centers performed by Bajaj et al. and found in Hepatology, show that potentially preventable second infections are predictors of mortality independent of liver disease severity.

Bacterial infections are an important cause of mortality in cirrhosis, but there is a paucity of multicenter studies. Bajaj et al. performed a prospective, cohort study of patients with cirrhosis with infections at eight North American tertiary-care hepatology centers. The results, found in Hepatology, show that 24 percent of patients who died within 30 days had higher admission model for endstage liver disease (MELD), lower serum albumin and second infections, but equivalent sequential organ failure (SOFA) scores. The team observed that the case fatality rate was highest for C. difficile, respiratory and spontaneous bacteremia, and lowest for spontaneous bacterial peritonitis and urinary infections. The researchers noted that model for mortality included admission MELD, heart rate, albumin and second infection as significant variables. Dr Bajaj's team concludes that "potentially preventable second infections are predictors of mortality independent of liver disease severity in this multicenter cirrhosis cohort."

Hepatology 2012: 56(6): 2328-2335

More on Cirrhosis

Blog: Special 15th Anniversary Collection from Clinical Gastroenterology and Hepatology

Oct. 11, 2017

Celebrate this milestone with a look back at landmark articles, commentaries and reviews. Read more on the AGA Journals blog.

Spotlight on Fellow-Led Quality Improvement Projects

Oct. 3, 2017

These 19 projects presented at DDW® 2017 showcase the extensive work being done by fellows to improve the quality of care provided to GI patients.

Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents

Oct. 1, 2017

Among HCV-infected patients treated with DAAs, SVR is associated with a considerable reduction in the risk of HCC; however, the risk for HCC remained high in patients with cirrhosis at the time of SVR.